Short Interest in Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH) Drops By 42.5%

Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH) was the recipient of a large drop in short interest during the month of December. As of December 31st, there was short interest totaling 160,518 shares, a drop of 42.5% from the December 15th total of 279,178 shares. Currently, 11.5% of the company’s stock are short sold. Based on an average daily trading volume, of 63,451 shares, the short-interest ratio is currently 2.5 days. Based on an average daily trading volume, of 63,451 shares, the short-interest ratio is currently 2.5 days. Currently, 11.5% of the company’s stock are short sold.

Institutional Trading of Shuttle Pharmaceuticals

A hedge fund recently bought a new stake in Shuttle Pharmaceuticals stock. Connective Capital Management LLC purchased a new stake in shares of Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH) in the third quarter, according to its most recent filing with the SEC. The firm purchased 100,535 shares of the company’s stock, valued at approximately $357,000. Connective Capital Management LLC owned 9.40% of Shuttle Pharmaceuticals at the end of the most recent quarter. 4.58% of the stock is owned by hedge funds and other institutional investors.

Shuttle Pharmaceuticals Stock Up 10.1%

NASDAQ:SHPH traded up $0.15 during trading hours on Friday, reaching $1.63. 4,574,671 shares of the company’s stock were exchanged, compared to its average volume of 537,255. The firm has a market capitalization of $2.61 million, a price-to-earnings ratio of -0.14 and a beta of -1.00. The company has a 50-day moving average of $1.77 and a 200 day moving average of $3.02. Shuttle Pharmaceuticals has a 1-year low of $1.26 and a 1-year high of $25.25.

Shuttle Pharmaceuticals (NASDAQ:SHPH) last posted its quarterly earnings data on Thursday, November 13th. The company reported ($1.05) EPS for the quarter.

Wall Street Analysts Forecast Growth

Several research firms have issued reports on SHPH. Wall Street Zen upgraded shares of Shuttle Pharmaceuticals to a “sell” rating in a research note on Saturday, November 8th. Weiss Ratings reissued a “sell (e+)” rating on shares of Shuttle Pharmaceuticals in a report on Monday, December 29th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock currently has a consensus rating of “Sell”.

About Shuttle Pharmaceuticals

Shuttle Pharmaceuticals Holdings, Inc, a clinical stage pharmaceutical company, develops novel therapies to cure cancers. It develops Ropidoxuridine, an oral halogenated pyrimidine to treat patients with brain tumors and sarcomas SP-1-161, an HDAC inhibitor that initiates the mutated in ataxia-telangiectasia response pathway for radiation sensitizing cancer cells and protecting normal cells; SP-2-225, a pre-clinical class IIb that effects on the regulation of the immune system; and SP-1-303, a pre-clinical selective Class I HDAC for the treatment of ER positive cancers .